Brief: CytomX Therapeutics FY Revenue USD 76.201 Million Vs. IBES Estimate USD 83.5 Million
16/03/2026 11:05
Mar 16 (Reuters) - CytomX Therapeutics FY cash & investments USD 124.385 million. FY net income USD -17.368 million FY operating expenses USD 98.565 million FY operating income USD -22.364 million
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway